4892-89-1

Usage

Chemical Properties

White to light yellow low melting crystals or oil

InChI:InChI=1/C10H21N3O/c1-3-12(4-2-11-1)5-6-13-7-9-14-10-8-13/h11H,1-10H2/p+3

Upstream product

• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 110-85-0 piperazine 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 61308-25-6 Chloroethylpiperazine 
• 3240-94-6 N-(2-chlorethyl)morpholine 
• 77279-24-4 tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate 
• 208167-83-3 tert-butyl 4-(2-chloroethyl)tetrahydro-1(2H)-pyrazinecarboxylate 

Downstream Products

• 1224936-72-4 C₁₉H₂₉BrFN₃O₃ 
• 1253796-53-0 C₂₃H₄₅N₃O₃ 
• 1280479-73-3 C₂₉H₃₇Cl₂FN₄O₂ 
• 1613082-54-4 1-(4-nitrobenzyl)-3-(4-(2-morpholinoethyl)piperazin-1-yl)quinoxalin-2(1H)-one 

Relevant academic research and scientific papers

Preparation method of 4-morpholinyl-2-ethylpiperazine

The invention discloses a preparation method of 4-morpholinyl-2-ethylpiperazine. The method comprises the following steps: (1) putting 2-hydroxyethylpiperazine and thionyl chloride into a first solvent, and performing a reaction to convert hydroxyl groups into chlorine to obtain a first reaction product; (2) putting the first reaction product obtained in step (1) and boc anhydride into a second solvent, and performing a reaction to obtain an N-boc protected second reaction product; (3) putting the second reaction product obtained in step (2), morpholine and an acid-binding agent into a third solvent at 20-50 DEG C, and performing a reaction to obtain a third reaction product; and (4) dissolving the third reaction product obtained in step (3) and an alkali in a fourth solvent, heating the obtained solution to 40-80 DEG C, performing a reaction for about 10-20 h, concentrating the obtained reaction solution, and extracting and concentrating the obtained concentrate to obtain the 4-morpholinyl-2-ethylpiperazine. Raw materials used in the method are cheap and are easy to obtain, the operation process is simple, and the purity of the obtained product is high and exceeds 99%.

Substituted formyldimethomorph (ethylpiperazine compound and) application thereof

The invention relates to substituted formyl morpholinoethyl piperazine compounds and an application thereof. The compounds are shown in a general formula (I) in the description, wherein R is phenyl, pyridyl, furyl, pyrazolyl, thiazolyl, thienyl or phenazi

CARBODITHIOATES WITH SPERMICIDAL ACTIVITY AND PROCESS FOR PREPARATION THEREOF

The present invention relates to the synthesis and biological evaluation of compound of formula I as spermicidal agents, and its pharmaceutically acceptable acid salt thereof. The invention provides bis(4- substituted-1-piperazinylthiocarbonyl) disulfide (when n = 0) and alkane-1,n-diylbis(4-substituted piperazine-1-carbodithioate) (when n = 0, 1, 2 or 3) as shown in figure 1 of the accompanying drawing. These compounds are found to be useful for spermicidal activity.

Natural product-based design, synthesis and biological evaluation of anthra[2,1-d]thiazole-6,11-dione derivatives from rhein as novel antitumour agents

Two series of novel 2-substituted 5,7-dihydroxyanthra[2,1-d]thiazole-6,11- dione derivatives from natural rhein were designed, synthesized and evaluated for their antitumour activities against human cancer cell lines A549 and HeLa in vitro.

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS

The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed

Tyrosine kinase inhibitors

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.